Vaccine approaches to malaria control and elimination: Insights from mathematical models

Vaccine

Volumn 33, Issue 52, 2015, Pages 7544-7550

  White, Michael T ^a   Verity, Robert ^a   Churcher, Thomas S ^a   Ghani, Azra C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Malaria; Mathematical model; Transmission; Trial design; Vaccine

Indexed keywords

MALARIA VACCINE;

ARTICLE; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; MALARIA; MALARIA CONTROL; MATHEMATICAL MODEL; PARASITE CLEARANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PUBLIC HEALTH; STATISTICAL MODEL; TRANSMISSION; VACCINATION;

CLINICAL TRIALS AS TOPIC; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MODELS, STATISTICAL; PLASMODIUM FALCIPARUM; PUBLIC HEALTH; VACCINATION;

EID: 84951146103     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.099     Document Type: Article

References (54)

1. WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014.
2. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012, 11:11.
3. Smith T.A., Chitnis N., Briet O.J.T., Tanner M. Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum. Trends Parasitol 2011, 27:190-196.
4. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875. The RTS SCTP.
5. N Engl J Med. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants 2012, 367:2284-2295. The RTS SCTP.
6. + T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4. Article number: 2836.
7. Seder R.A., Chang L.-J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
8. Roestenberg M., Teirlinck A.C., McCall M.B.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
9. van Schaijk B.C.L., Ploemen I.H.J., Annoura T., Vos M.W., Foquet L., van Gemert G.-J., et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. Elife 2014, 3:e03582.
10. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008, 3.
11. Nikolaeva D., Draper S.J., Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines 2015, 19:1-28.
12. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y.M., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005, 23:3131-3138.
13. Nosten F., Luxemburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E., et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in Northwestern Thailand. Lancet 1996, 348:701-707.
14. Bejon P., White M.T., Olotu A., Bojang K., Lusingu J., Salim N., et al. Efficacy of RTS, S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013, 13(4):319-327.
15. White M.T., Bejon P., Olotu A., Griffin J.T., Bojang K., Lusingu J., et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS, S malaria vaccine. BMC Med 2014, 12:117.
16. Bousema T., Dinglasan R.R., Morlais I., Gouagna L.C., van Warmerdam T., Awono-Ambene P.H., et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One 2012, 7(8):e42821.
17. Churcher T.S., Blagborough A.M., Delves M., Ramakrishnan C., Kapulu M.C., Williams A.R., et al. Measuring the blockade of malaria transmission: an analysis of the Standard Membrane Feeding Assay. Int J Parasitol 2012, 42:1037-1044.
18. Griffin J.T., Hollingsworth T.D., Okell L.C., Churcher T.S., White M., Hinsley W., et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010, 7.
19. Smith T., Ross A., Maire N., Chitnis N., Studer A., Hardy D., et al. Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine. PLoS Med 2012, 9(1):e1001157.
20. Wenger E.A., EckhoffP.A. A mathematical model of the impact of present and future malaria vaccines. Malar J 2013, 12:126.
21. White L.J., Maude R.J., Pongtavornpinyo W., Saralamba S., Aguas R., Effelterre T.V., et al. The role of simple mathematical models in malaria elimination strategy design. Malar J 2009, 8(14 (September)):212.
22. Reiner R.C., Perkins T.A., Barker C.M., Niu T., Fernando Chaves L., Ellis A.M., et al. A systematic review of mathematical models of mosquito-borne pathogen transmission: 1970-2010. J R Soc Interface 2013, 10(81).
23. Griffin J.T., Ferguson N.M., Ghani A.C. Estimates of the changing age-burden of P. falciparum malaria disease in sub-Saharan Africa. Nat Commun 2014, 5. Article number: 3136.
24. Doherty J.F., Pinder M., Tornieporth N., Carton C., Vigneron L., Milligan P., et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS, S/SBAS2 in semi-immune adults in the Gambia. Am J Trop Med Hyg 1999, 61:865-868.
25. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J Infect Dis 1998, 178:1139-1144.
26. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
27. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11:57-64.
28. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10.
29. Lievens M., Aponte J.J., Williamson J., Mmbando B., Mohamed A., Bejon P., et al. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J 2011, 10:222.
30. Halloran E.M., Longini I.M., Struchiner C.J. Design and analysis of vaccine studies 2010, Springer, New York.
31. White M.T., Griffin J.T., Akpogheneta O., Conway D.J., Koram K.A., Riley E.M., et al. Dynamics of the antibody response to Plasmodium falciparum infection in African children. J Infect Dis 2014, 210:1115-1122.
32. Durham L.K., Longini I.M., Halloran M.E., Clemens J.D., Nizam A., Rao M. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 1998, 147:948-959.
33. Kanaan M.N., Farrington C.P. Estimation of waning vaccine efficacy. J Am Stat Assoc 2002, 97:389-397.
34. Grambsch P.M., Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-526.
35. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
36. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420.
37. + T Cell responses and protection against Plasmodium falciparum infection. PLoS One 2013, 8(4):e61395.
38. Bojang K.A., Milligan P.J.M., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS, S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet 2001, 358:1927-1934.
39. Polhemus M.E., Remich S.A., Ogutu B.R., Waitumbi J.N., Otieno L., Apollo S., et al. Evaluation of RTS, S/AS02A and RTS, S/AS01B in adults in a high malaria transmission area. PLoS One 2009, 4(7):e6465.
40. Olotu A., Lusingu J., Leach A., Lievens M., Vekemans J., Msham S., et al. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011, 11:102-109.
41. Olotu A., Fegan G., Wambua J., Nyangweso G., Awuondo K.O., Leach A., et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120.
42. Campo J.J., Sacarlal J., Aponte J.J., Aide P., Nhabomba A.J., Dobano C., et al. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS, S/AS02 in Mozambique. Vaccine 2014, 32:2209-2216.
43. Bejon P., Cook J., Bergmann-Leitner E., Olotu A., Lusingu J., Mwacharo J., et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS, S/AS01(E) on blood stage immunity in young children. J Infect Dis 2011, 204:9-18.
44. Final results from a phase 3, individually randomised, controlled trial of the RTS, S/AS01 malaria vaccine in African infants and children, including an evaluation of the efficacy of a booster dose. Lancet 2015, 386(9988):31-45. The RTS SCTP, 4 July 2015.
45. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014, 11(7):e1001685. The RTS SCTP.
46. Sinden R.E., Blagborough A.M., Churcher T., Ramakrishnan C., Biswas S., Delves M.J. The design and interpretation of laboratory assays measuring mosquito transmission of Plasmodium. Trends Parasitol 2012, 28:457-465.
47. Smith D.L., Drakeley C.J., Chiyaka C., Hay S.I. A quantitative analysis of transmission efficiency versus intensity for malaria. Nat Commun 2010, 1.
48. Delrieu I., Leboulleux D., Ivinson K., Gessner B.D., Chandramohan D., Churcher T.S., et al. Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. Vaccine 2015, 33:1518-1526.
49. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Infectious diseases of humans: dynamics and control 1991: vii+757 pp.
50. From malaria control to malaria elimination: a manual for elimination scenario planning 2014, WHO, World Health Organization, Geneva.
51. Churcher T.S., Trape J.-F., Cohuet A. Human-to-mosquito transmission efficiency increases as malaria is controlled. Nat Commun 2015, 6:6054.
52. Churcher T.S., Bousema T., Walker M., Drakeley C., Schneider P., Ouedraogo A.L., et al. Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. Elife 2013, 2:e00626.
53. White M.T., Smith D.L. Synergism from combinations of infection-blocking malaria vaccines. Malar J 2013, 12:280.
54. Hill A.V.S. Vaccines against malaria. Philos Trans R Soc B: Biol Sci 2011, 366:2806-2814.